Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

N Engl J Med. 2021 Feb 18;384(7):673-674. doi: 10.1056/NEJMc2030164.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antigens, CD19
  • Follow-Up Studies
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Progression-Free Survival
  • Receptors, Chimeric Antigen / therapeutic use*
  • Treatment Outcome

Substances

  • Antigens, CD19
  • Receptors, Chimeric Antigen